A prospective randomized trial of α2B-Interferon/γ-Interferon or the combination in advanced metastatic renal cell carcinoma

Journal of Biological Response Modifiers

Volumn 7, Issue 6, 1988, Pages 540-545

  Foon, K ^a   Doroshow, J ^b   Bonnem, E ^c   Fefer, A ^d   Graham, S ^e   Grosh, B ^f   Narayan, P ^g   Elias, L ^h   Harvey, H ⁱ   Schulof, R ^j   Williams, R ^k   Rinehart, J ^l   Zekan, P ^m   Catalona, W ⁿ   Dillman, R ^o   Salmon, S ^p   Galasso, F ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b City of Hope   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e EMORY UNIVERSITY   (United States)

^f VANDERBILT UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF NEW MEXICO   (United States)

ⁱ PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^j GEORGE WASHINGTON UNIVERSITY   (United States)

^k UNIVERSITY OF IOWA   (United States)

^l OHIO STATE UNIVERSITY   (United States)

^m WAKE FOREST SCHOOL OF MEDICINE   (United States)

ⁿ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p UNIVERSITY OF ARIZONA   (United States)

more..

Author keywords

Advanced metastatic renal cell carcinoma; Alpha interferon; Gammainterferon; Key Words; Synergism

Indexed keywords

ALPHA2B INTERFERON; GAMMA INTERFERON;

ADVANCED CANCER; AGE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

CARCINOMA, RENAL CELL; DRUG THERAPY, COMBINATION; HUMAN; INTERFERON ALFA-2B; INTERFERON TYPE I, RECOMBINANT; INTERFERON TYPE II; RECOMBINANT PROTEINS;

EID: 0023737411     PISSN: 07326580     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Quesada JR, Swanson DA, Trindale A, et al. Renal cell carcinoma: Antitumor effects of leucocyte interferon. Cancer Res 1983;43:940-7.
2. Quesada JR, Swanson DA, Gutterman JU. Phase II trial of alpha interferon in metastatic renal cell carcinoma: A progress report. J Clin Oncol 1985 ;3:1086-92.
3. Muss HB, Costanzi JJ, Leavitt R, et al. Recombinant alpha interferon in renal cell carcinoma: A randomized trial of two routes of administration. J Clin Oncol 1987;5:286-91.
4. Muss HB. Interferon therapy for renal cell carcinoma. Semin Oncol 1987;14(suppl):36-42.
5. Harvey HA, Lipton A, White DA, et al. Pharmacokinetic study of partially pure gamma interferon in cancer patients. Proc Am Soc Clin Oncol 1983;2:46.
6. Gutterman JU, Rosenblum MG, Rios A, et al. Pharmacokinetic study of partially pure gamma interferon in cancer patients. Cancer Res 1984;44:4164-71.
7. Garnick MB, Reich SD, Maxwell B, et al. Phase I/II trial of recombinant interferon gamma in advanced renal cell carcinoma. TNO Meeting, Tampa, Florida, October 17, 1985, Abstract 139
8. Quesada JR, Kurzrock R, Sherwin SA, Gutterman JU. Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. 7 Biol Response Mod 1987;6:20-7.
9. Fleischman WR, Georgiades JA, Osborne LC, et al. Potentiation of interferon activity by mixed preparations of fibroblast and immune interferon. Infect Immun 1979;26:248-53.
10. Zerial A, Hovanessian AG, Stefanos S. Synergistic activities of type I (a,ß) and type II (?) murine interferons. Antiviral Res 1982;2:227-39.
11. Schwarz LA, Fleischmann CM, Fleischmann WR. Potentiation of interferon’s antiviral activity by the mutually synergistic interaction of Mu IFN a/ß and Mu IFN ?. J Biol Response Mod 1984;3:608-12.
12. Fleischman WR. Potentiation of direct anticellular activity of mouse interferon: Mutual synergism and interferon concentration dependence. Cancer Res 1982;42:869-75.
13. Fleischmann WR Jr, Kleyn KM, Baron S. Potentiation of antitumor effect of virus induced interferon by mouse immune interferon preparations. JNCI 1980;65:963-6.
14. Fleischmann WR Jr, Fleischmann CM, Fiers W. Potentiation of interferon action by mixtures of recombinant DNA derived human interferons. Antiviral Res 1984;4:357-60.
15. Bonnern EM, Muss H, Caponera M, et al. Phase I study of r alfa-2b-interferon and r gamma interferon in patients with advanced malignancy. Proc Am Soc Clin Oncol 1987;6:234.
16. Kurzrock R, Rosenblum MG, Quesada JR, et al. Pharmacokinetics, tolerance and biological activity of a combination of recombinant interferon alpha-A and recombinant interferon gamma in cancer patients. Proc Am Soc Clin Oncol 1985;5:226.
17. Selby P, Kohn J, Raymond J, et al. Nephrotic syndrome during treatment with interferon. Br Med J 1985;290:1180.
18. Auerbach SD, Austin HA, Sherwin SA, et al. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis fungoides. N EnglJ Med 1984;310:32-5.